← Back to Discoveries | PubMed 2026-03-25 synthesized

Rapid identification of African swine fever virus in diagnostic samples using CRISPR-Cas.

Kambakam S, Thomas J, Robbe-Austerman S, Shanmuganatham K, Palinski R

Summary

0.8/10

This article is about detecting African swine fever in pigs using CRISPR-Cas technology, not plant science. It describes a field-deployable diagnostic test that identifies the virus in blood samples with accuracy matching laboratory PCR tests.

Key Findings

1

CRISPR-Cas12a assay achieved 98.3% sensitivity in whole blood samples from ASFV-suspect cases

2

Visual detection method provides comparable results to real-time PCR (rtPCR) laboratory testing

3

Low-cost point-of-care test can be deployed in the field for rapid diagnosis during outbreaks

description

Original Abstract

African swine fever virus (ASFV) is a highly transmissible pathogen affecting swine, causing a devastating disease with high mortality rates in naive populations. Given the likelihood of significant economic impacts associated with an ASF outbreak, considerable resources have been allocated in the United States to safeguard the swine industry against this threat. Ongoing outbreaks of ASF in the Dominican Republic and Haiti further threaten the U.S. swine industry, given their proximity and involvement in movement to and from North America. Although surveillance programs are ongoing, limited point-of-care (POC) tests are available during outbreaks with the sensitivity and specificity standards of laboratory testing (e.g., real-time PCR [rtPCR]). However, the recently developed CRISPR-Cas-based testing systems may offer comparable high-quality results. We sought to develop a low-cost visual detection method for ASFV by employing a recombinase polymerase amplification (RPA)-dependent CRISPR-Cas12a technique that can be utilized in the field as a POC assay. Our CRISPR-Cas12a assay had comparable sensitivity and specificity to rtPCR, both visually and when quantified using a fluorescence reader. In whole blood samples from ASFV-suspect or ASFV-negative cases, our CRISPR assay achieved a sensitivity of 98.3% (10